Structural Basis for Insulin Resistance Mediated by IRS-1 Serine Phosphorylation

IRS-1 丝氨酸磷酸化介导的胰岛素抵抗的结构基础

基本信息

  • 批准号:
    7286368
  • 负责人:
  • 金额:
    $ 4.96万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2006
  • 资助国家:
    美国
  • 起止时间:
    2006-09-01 至 2009-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The Shoelson Lab at the Joslin Diabetes Center has been instrumental in showing that a subacute inflammatory process links obesity to the development of insulin resistance and type 2 diabetes. In terms of the biochemical events that mediate the inflammatory response, two intracellular pathways are activated in parallel, one mediated by the c-Jun N-terminal kinase (JNK) and the other by IKK beta and NF-kappaB. Studies of NF-kappaB activation in insulin resistance have centered mostly on the transcriptional regulation of proinflammatory cytokines and chemokines, such as TNF-alpha, MCP-1, IL-6, IL-1 beta and resistin. In contrast, studies with JNK have focused on the direct phosphorylation of insulin receptor substrate 1 (IRS-1). Insulin receptor (IR) is a tyrosine kinase that is activated by insulin binding. Activated IR binds to the IRS-1 phosphotyrosine-binding (PTB) domain and sequentially phosphorylates IRS-1 at numerous tyrosine sites dispersed throughout its primary sequence. The phosphorylated tyrosine residues engage and activate SH2 domain containing proteins that propagate the signal into the cell. JNK phosphorylates human IRS-1 at two distinct sites, Ser307 and Ser312, and when these sites are phosphorylated; IRS-1 neither binds IR nor activates cellular signaling. Phosphorylation at Ser312 has been studied in greatest detail and shown to correlate with the development of insulin resistance in rodent models and diabetic, insulin-resistant patients. While these findings link inflammation to the inhibition of insulin signaling, they do not provide a molecular mechanism. Given what is known about IR and IRS-1 structure, and the fact that Ser307 and Ser312 are located approximately 50 residues C-terminal to the PTB domain (IRS-1 residue 156-260) in an otherwise disordered region of the protein, it is not at all obvious how phosphorylation at these sites causes insulin resistance. I have hypothesized that JNK phosphorylation of IRS-1 inhibits PTB domain binding to IR as follows. Since Ser307 and Ser312 are in a disordered and apparently flexible region of the protein, these sites are free to loop around the PTB domain and interact with its phosphotyrosine binding site. Phosphoserine residues have never been shown to bind PTB domains, but I hypothesize that this occurs because they are sufficiently close that the intermolecular interaction is energetically (entropically) favored. Engagement of its PTB domain by pSer307 or pSer312 would auto-inhibit IRS-1 by preventing it from docking as usual to pTyr960 of the insulin receptor. We will test this hypothesis by generating phosphoserine extended IRS-1 PTB domain by expressed protein ligation (EPL) and by measuring binding affinities with isothermal titration calorimetry. We will also solve the crystal structure of the self-inhibited form of the IRS-1 PTB domain.
描述(由申请人提供):乔斯林糖尿病中心的Shoelson实验室有助于表明亚急性炎症过程将肥胖与胰岛素抵抗和2型糖尿病的发展联系起来。在介导炎症反应的生化事件方面,两种细胞内途径平行激活,一种由c-Jun N-末端激酶(JNK)介导,另一种由IKK β和NF-κ B介导。胰岛素抵抗中NF-κ B活化的研究主要集中在促炎细胞因子和趋化因子如TNF-α、MCP-1、IL-6、IL-1 β和β-内酰胺酶的转录调节上。相反,JNK的研究集中在胰岛素受体底物1(IRS-1)的直接磷酸化。胰岛素受体(IR)是一种酪氨酸激酶,通过与胰岛素结合而被激活。活化的IR结合IRS-1磷酸酪氨酸结合(PTB)结构域,并在分散在其一级序列中的许多酪氨酸位点连续磷酸化IRS-1。磷酸化的酪氨酸残基接合并激活含有SH 2结构域的蛋白质,该蛋白质将信号传播到细胞中。JNK在两个不同的位点(Ser 307和Ser 312)磷酸化人IRS-1,当这些位点被磷酸化时,IRS-1既不结合IR也不激活细胞信号传导。Ser 312的磷酸化已被最详细地研究,并显示与啮齿动物模型和糖尿病胰岛素抵抗患者中胰岛素抵抗的发展相关。虽然这些发现将炎症与胰岛素信号的抑制联系起来,但它们并没有提供分子机制。已知IR和IRS-1结构,以及Ser 307和Ser 312位于PTB结构域(IRS-1残基156-260)C-末端约50个残基的事实,在蛋白质的其他无序区域中,这些位点的磷酸化如何引起胰岛素抗性根本不明显。我假设IRS-1的JNK磷酸化抑制PTB结构域与IR的结合,如下所述。由于Ser 307和Ser 312位于蛋白质的无序和明显的柔性区域,这些位点可以自由地围绕PTB结构域形成环并与其磷酸酪氨酸结合位点相互作用。磷酸丝氨酸残基从未被证明可以结合PTB结构域,但我假设这是因为它们足够接近,分子间的相互作用在能量(熵)上是有利的。其PTB结构域与pSer 307或pSer 312的结合将通过阻止IRS-1与胰岛素受体的pTyr 960正常对接而自动抑制IRS-1。我们将通过表达蛋白连接(EPL)产生磷酸丝氨酸延伸的IRS-1 PTB结构域和用等温滴定量热法测量结合亲和力来测试这一假设。我们还将解决IRS-1 PTB结构域的自抑制形式的晶体结构。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SangYoun Park其他文献

SangYoun Park的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SangYoun Park', 18)}}的其他基金

Structural Basis for Insulin Resistance Mediated by IRS-1 Serine Phosphorylation
IRS-1 丝氨酸磷酸化介导的胰岛素抵抗的结构基础
  • 批准号:
    7222287
  • 财政年份:
    2006
  • 资助金额:
    $ 4.96万
  • 项目类别:
Structural Basis for Insulin Resistance Mediated by IRS-1 Serine Phosphorylation
IRS-1 丝氨酸磷酸化介导的胰岛素抵抗的结构基础
  • 批准号:
    7473204
  • 财政年份:
    2006
  • 资助金额:
    $ 4.96万
  • 项目类别:

相似国自然基金

帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
  • 批准号:
    32170319
  • 批准年份:
    2021
  • 资助金额:
    58.00 万元
  • 项目类别:
    面上项目
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
  • 批准号:
  • 批准年份:
    2021
  • 资助金额:
    58 万元
  • 项目类别:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
  • 批准号:
    31672538
  • 批准年份:
    2016
  • 资助金额:
    62.0 万元
  • 项目类别:
    面上项目
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
  • 批准号:
    31372080
  • 批准年份:
    2013
  • 资助金额:
    80.0 万元
  • 项目类别:
    面上项目
P53 binding protein 1 调控乳腺癌进展转移及化疗敏感性的机制研究
  • 批准号:
    81172529
  • 批准年份:
    2011
  • 资助金额:
    58.0 万元
  • 项目类别:
    面上项目
DBP(Vitamin D Binding Protein)在多发性硬化中的作用和相关机制的蛋白质组学研究
  • 批准号:
    81070952
  • 批准年份:
    2010
  • 资助金额:
    35.0 万元
  • 项目类别:
    面上项目
研究EB1(End-Binding protein 1)的癌基因特性及作用机制
  • 批准号:
    30672361
  • 批准年份:
    2006
  • 资助金额:
    24.0 万元
  • 项目类别:
    面上项目

相似海外基金

Analysis of affinity changes of actin-binding proteins by mechanical response of actin molecular structures
通过肌动蛋白分子结构的机械响应分析肌动蛋白结合蛋白的亲和力变化
  • 批准号:
    19K06603
  • 财政年份:
    2019
  • 资助金额:
    $ 4.96万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Regulation of miRNA biogenesis in Arabidopsis - An RNA-affinity based approach to characterize pri-miRNA stem-loop binding proteins
拟南芥中 miRNA 生物合成的调控 - 一种基于 RNA 亲和力的方法来表征 pri-miRNA 茎环结合蛋白
  • 批准号:
    314773174
  • 财政年份:
    2016
  • 资助金额:
    $ 4.96万
  • 项目类别:
    Research Grants
Developing high affinity ligands of glycan binding proteins
开发聚糖结合蛋白的高亲和力配体
  • 批准号:
    9166443
  • 财政年份:
    2016
  • 资助金额:
    $ 4.96万
  • 项目类别:
Development of the affinity matrix for comprehensive analysis of ligand- binding proteins
开发用于综合分析配体结合蛋白的亲和矩阵
  • 批准号:
    22710219
  • 财政年份:
    2010
  • 资助金额:
    $ 4.96万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Research on techniques for the identification of carbohydrate binding proteins using glycome-wide oligosaccharides as affinity probes
以全糖组寡糖为亲和探针的糖结合蛋白鉴定技术研究
  • 批准号:
    18550145
  • 财政年份:
    2006
  • 资助金额:
    $ 4.96万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Engineering high affinity integrin binding proteins
工程化高亲和力整合素结合蛋白
  • 批准号:
    7194212
  • 财政年份:
    2004
  • 资助金额:
    $ 4.96万
  • 项目类别:
Engineering high affinity integrin binding proteins
工程化高亲和力整合素结合蛋白
  • 批准号:
    6712379
  • 财政年份:
    2004
  • 资助金额:
    $ 4.96万
  • 项目类别:
Engineering high affinity integrin binding proteins
工程化高亲和力整合素结合蛋白
  • 批准号:
    7064760
  • 财政年份:
    2004
  • 资助金额:
    $ 4.96万
  • 项目类别:
Engineering high affinity integrin binding proteins
工程化高亲和力整合素结合蛋白
  • 批准号:
    6892795
  • 财政年份:
    2004
  • 资助金额:
    $ 4.96万
  • 项目类别:
Engineering high affinity integrin binding proteins
工程化高亲和力整合素结合蛋白
  • 批准号:
    7360302
  • 财政年份:
    2004
  • 资助金额:
    $ 4.96万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了